Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director dealings: Diurnal trio dip in after EMA submission in December

Mon, 16th Jan 2017 15:08

(ShareCast News) - A trio of Diurnal Group directors bought shares in the hormone disease specialist, which remain little higher than the low reached late last year.Chairman Peter Allen bought 40,000 shares at 105p and non-executive directors Sam Williams and John Goddard bought 9,248 each at a price of 108p.Diurnal, which floated on AIM in December 2015 market authorisation in late 2017, last month submitted the marketing application to the European Medicines Agency for Infacort, which has the potential to be the first licensed treatment in Europe for Adrenal Insufficiency (AI) specifically designed for use in children under six years of age.This was made on the back of "highly statistically significant" data from clinical trials, with the EMA having already approved a paediatric investigation plan (PIP) for Infacort that set out the regulatory pathway to market authorisation.Diurnal anticipates market authorisation in late 2017, with product revenues expected from early 2018 and the company estimating the total market for paediatric AI and the related condition Congenital Adrenal Hyperplasia in Europe is approximately $28m per year.Top Director BuysDiurnal Group (DNL)Director name: Allen,PeterAmount purchased: 40,000 @ 105.00pValue: £42,000.00Diurnal Group (DNL)Director name: Goddard,JohnAmount purchased: 9,248 @ 108.00pValue: £9,987.84Diurnal Group (DNL)Director name: Williams,SamAmount purchased: 9,248 @ 108.00pValue: £9,987.84Jardine Lloyd Thompson Group (JLT)Director name: Walsh,NicholasAmount purchased: 1,000 @ 997.42pValue: £9,974.25Haydale Graphene Industries (HAYD)Director name: Gibbs,Raymond (Ray) JohnAmount purchased: 4,353 @ 160.00pValue: £6,964.80Fidelity Asian Values (FAS)Director name: Stott,GrahameAmount purchased: 4,000 @ 31.00pValue: £1,240.00Vodafone Group (VOD)Director name: Schellekens,Ronald Amount purchased: 118 @ 212.45pValue: £250.69Sthree (STHR)Director name: Smith,AlexAmount purchased: 65 @ 319.00pValue: £207.35Sthree (STHR)Director name: Elden,GaryAmount purchased: 64 @ 319.00pValue: £204.16Supergroup (SGP)Director name: Sutherland ,EuanAmount purchased: 9 @ 1,712.00pValue: £154.08Supergroup (SGP)Director name: Cartwright,Andrea Amount purchased: 9 @ 1,712.00pValue: £154.08Aviva (AV.)Director name: Amin,NitinbhaiAmount purchased: 31 @ 480.80pValue: £149.05Shoe Zone (SHOE)Director name: Davis ,Nicholas (Nick)Amount purchased: 7,000 @ 1.80pValue: £126.00Top Director SellsRenew Holdings (RNWH)Director name: Samuel,JohnAmount sold: 112,518 @ 434.00pValue: £488,328.14Lindsell Train Inv Trust (LTI)Director name: Landman,RoryAmount sold: 100 @ 86,500.00pValue: £86,500.00
More News
10 Jan 2019 11:33

Diurnal Shares Surge As Secures Second Patent For Chronocort In US

LONDON (Alliance News) - Diurnal Group PLC on Thursday said the US Patent & Trademark Office has granted the company a second US patent for Chronocort.Diurnal shares almost tripled on a

Read more
10 Jan 2019 11:26

Diurnal awarded US patent for Chronocort product

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Thursday that the US Patent and Trademark Office (USPTO) has granted a second US patent for its 'Chronocort' modified release hydrocortisone product.

Read more
17 Oct 2018 12:10

Diurnal halts US development of Chronocort after European trials come up short

(Sharecast News) - Speciality pharmaceutical company Diurnal has put all development activities for its modified release hydrocortisone product on hold after it failed to meet its primary endpoint in a recent phase-three European trial.

Read more
17 Oct 2018 10:41

Diurnal Puts All Chronocort US Development Activities On Hold

LONDON (Alliance News) - Diurnal Group PLC said Wednesday it decided to put all US development activities for its Chronocort product on hold, after it failed to meet its primary objective in its a

Read more
8 Oct 2018 17:07

LONDON MARKET CLOSE: Stocks End Lower On Chinese And Italian Woes

LONDON (Alliance News) - Stocks closed lower Monday on the actions of the Chinese and Italian governments, as the pound continued its fall on news from 10 Downing Street there remains "big in of

Read more
8 Oct 2018 15:15

Diurnal Group Child Adrenal Insufficiency Drug Approved In Scotland

LONDON (Alliance News) - Diurnal Group PLC said Monday the Scottish Medicines Consortium approved the routine use of Alkindi, a first-line treatment of young children with adrenal insufficiency to

Read more
8 Oct 2018 12:00

LONDON MARKET MIDDAY: China Prompts Sell-Off In Europe; Insurers Fall

LONDON (Alliance News) - Share prices in London had slipped firmly into the red by midday on Monday following a slump in Chinese equities overnight."Europe is following the Asian lead, with a 3%

Read more
8 Oct 2018 10:33

WINNERS & LOSERS SUMMARY: French Connection In Vogue On Possible Sale

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 1.0%. The asset manager confirmed it is in to

Read more
8 Oct 2018 09:29

Diurnal's endocrine drug does not meet trial objective

(Sharecast News) - Clinical trials of Diurnal Group's Chronocort drug failed to meet the primary objective of proving superior to conventional therapy in endocrine control over a 24-hour period.

Read more
8 Oct 2018 08:54

Shares In IP Group, Diurnal Suffer After Chronocort Trial Disappoints

LONDON (Alliance News) - Diurnal Group PLC said Monday its phase-three European trial of Chronocort did not meet its primary objective, causing shares in the pharmaceutical company to property IP

Read more
8 Oct 2018 07:48

LONDON MARKET PRE-OPEN: Lower Call; Schroders Confirms Lloyds Talks

LONDON (Alliance News) - Stocks in London on Monday are set to continue last week's slide, fuelled by concerns that strong US economic data will lead to a quickened pace of interest rate hikes.In

Read more
5 Oct 2018 09:20

Diurnal kicks off adrenal condition trial with first patients

(Sharecast News) - Specialist pharmaceutical company Diurnal said it had enrolled the first two patients in its US-based Chronocort phase III trial for adults with congenital adrenal hyperplasia (CAH).

Read more
5 Oct 2018 08:16

Diurnal Enrols First Patients In Phase Three US Chronocort Trial

LONDON (Alliance News) - Pharmaceutical company Diurnal Group PLC on Friday said the first two patients have been enrolled into its phase three US trial of Chronocort.Chronocort is a form a

Read more
20 Sep 2018 09:56

Diurnal Generates First Revenue But Loss Deepens As Costs Rise

LONDON (Alliance News) - Pharmaceutical firm Diurnal Group PLC said Thursday its annual loss deepened amid higher costs despite generating its first revenue from drug sales.For the year the

Read more
15 Aug 2018 12:39

German Body Says Diurnal Alkindi's Benefit Over Generic Not Proven

LONDON (Alliance News) - Diurnal Group PLC said Wednesday a German body published a study which says that the benefit of the company's product Alkindi over generic hydrocortisone has not been

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.